| Novel serum tumor marker, RCASl, in pancreatic diseases |
| |
| 引用本文： | Koji Yamaguchi,Munechika Enjoji,Manabu Nakashima,Makoto Nakamuta,Takashi Watanabe,Masao Tanaka. Novel serum tumor marker, RCASl, in pancreatic diseases[J]. World journal of gastroenterology : WJG, 2005, 0(33) |
| |
| 作者姓名： | Koji Yamaguchi Munechika Enjoji Manabu Nakashima Makoto Nakamuta Takashi Watanabe Masao Tanaka |
| |
| 作者单位： | Department of Surgery and Oncology Graduate School of Medicine Kyushu University Japan，Medicine Bioregulatory Sciences Graduate School of Medical Sciences Kyushu University Japan，Department of Molecular Immunology Medical Institute of Bioregulation Faculty of Medicine，Kyushu University，Japan，Medicine Bioregulatory Sciences Graduate School of Medical Sciences Kyushu University Japan，Department of Molecular Immunology Medical Institute of Bioregulation Faculty of Medicine Kyushu University Japan，Department of Surgery and Oncology Graduate School of Medicine Kyushu University Japan |
| |
| 摘 要： | AIM: As tumor markers for pancreatic carcinoma, carcinoembryonic antigen (CEA) and carbohydrate antigen (CA) 19-9 have been used, but the sensitivity and specificity are not enough for the diagnosis of pancreatic carcinoma. METHODS: A novel serum tumor marker, RCAS1, was compared with two conventional serum tumor markers, CEA (highly specific for pancreatic cancer) and CA 19-9 (highly sensitive for pancreatic cancer), in 48 patients with pancreatic exocrine tumors. RESULTS: When the diagnosis of benign or malignant conditions was examined by one tumor marker, the sensitivity of RCAS1 alone (55%) was higher than that of CEA alone (27%) and the specificity of RCAS1 alone (92%) was greater than that of CA19-9 alone (78%). When examined by a combination of two markers, the sensitivity of a combination of RCAS1 and CA19-9 (95%) was superior to those of CA19-9 alone (78%), RCAS1 alone (55%, P = 0.002), CEA alone (27%) (P<0.001), RCAS1 and CEA (59%) and CA19-9 and CEA (82%). CONCLUSION: These results suggest that the combination of RCAS1 and CA19-9 is highly sensitive for pancreatic carcinoma.
|
Novel serum tumor marker, RCASl, in pancreatic diseases |
| |
| Koji Yamaguchi,Masao Tanaka. Novel serum tumor marker, RCASl, in pancreatic diseases[J]. World journal of gastroenterology : WJG, 2005, 0(33) |
| |
| Authors: | Koji Yamaguchi Masao Tanaka |
| |
| Affiliation: | Koji Yamaguchi,Masao Tanaka,Department of Surgery and Oncology,Graduate School of Medicine,Kyushu University,Japan Munechika Enjoji,Makoto Nakamuta,Medicine Bioregulatory Sciences,Graduate School of Medical Sciences,Kyushu University,Japan Manabu Nakashima,Takashi Watanabe,Department of Molecular Immunology,Medical Institute of Bioregulation,Faculty of Medicine,Kyushu University,Japan |
| |
| Abstract: | AIM: As tumor markers for pancreatic carcinoma, carcinoembryonic antigen (CEA) and carbohydrate antigen (CA) 19-9 have been used, but the sensitivity and specificity are not enough for the diagnosis of pancreatic carcinoma. METHODS: A novel serum tumor marker, RCAS1, was compared with two conventional serum tumor markers, CEA (highly specific for pancreatic cancer) and CA 19-9 (highly sensitive for pancreatic cancer), in 48 patients with pancreatic exocrine tumors. RESULTS: When the diagnosis of benign or malignant conditions was examined by one tumor marker, the sensitivity of RCAS1 alone (55%) was higher than that of CEA alone (27%) and the specificity of RCAS1 alone (92%) was greater than that of CA19-9 alone (78%). When examined by a combination of two markers, the sensitivity of a combination of RCAS1 and CA19-9 (95%) was superior to those of CA19-9 alone (78%), RCAS1 alone (55%, P = 0.002), CEA alone (27%) (P<0.001), RCAS1 and CEA (59%) and CA19-9 and CEA (82%). CONCLUSION: These results suggest that the combination of RCAS1 and CA19-9 is highly sensitive for pancreatic carcinoma. |
| |
| Keywords: | RCASl CEA CA19-9 Pancreatic diseases |
| 本文献已被 CNKI 等数据库收录！ |
|
